Pediatric non-Hodgkin's lymphoma

被引：26

作者：

Gross T.G. ^{[1
]}

Termuhlen A.M. ^{[1
]}

机构：

[1] Department of Pediatrics, The Ohio State University School of Medicine, Division of Hematology/Oncology/BMT, Columbus, OH 43205

来源：

Current Oncology Reports | 2007年 / 9卷 / 6期

关键词：

Anaplastic Lymphoma Kinase; Malt Lymphoma; Burkitt Lymphoma; Prophylactic Cranial Irradiation; Lymphoblastic Lymphoma;

D O I：

10.1007/s11912-007-0064-6

中图分类号：

学科分类号：

摘要：

Non-Hodgkin's lymphoma (NHL) accounts for 7% of cancer in children and adolescents in the United States, or approximately 1000 cases annually. NHL in the pediatric population differs from that observed in adult patients with respect to staging systems, histologic subtypes of disease, treatment, and outcomes. Although more than 90% of pediatric NHL is of high-grade histology, more than 80% of patients achieve long-term event-free survival with modern therapy. This review focuses on current treatments for pediatric NHL and some of the differences between NHL observed in pediatric and adult patients. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：459 / 465

页数：6

共 50 条

[11]

Miles R.R., Raphael M., McCarthy K., Et al., Expression of BCL2 and C-MYC in pediatric diffuse large B-cell lymphoma, Pediatr Blood Cancer, 46, (2006)

[12]

Dave S.S., Fu K., Wright G.W., Et al., Molecular diagnosis of Burkitt's lymphoma, N Engl J Med, 354, pp. 2431-2442, (2006)

[13]

Seidemann K., Tiemann M., Lauterbach I., Et al., Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: Treatment and results from three therapeutic studies of the Berlin-Frankfurt-Münster Group, J Clin Oncol, 2, pp. 1782-1789, (2003)

[14]

Patte C., Auperin A., Gerard M., Et al., Results of randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: It is possible to reduce treatment for early responding patients, Blood, 109, pp. 2773-2780, (2007)

[15]

Rosenwald A., Wright G., Leroy K., Et al., Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma, J Exp Med, 198, pp. 851-862, (2003)

[16]

Cairo M.S., Gerard M., Sposto R., Et al., Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents, Blood, 109, pp. 2736-2743, (2007)

[17]

Woessmann W., Seidemann K., Mann G., Et al., The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: A report of the BFM Group Study NHL-BFM95, Blood, 105, pp. 948-958, (2005)

[18]

Link M.P., Shuster J.J., Donaldson S.S., Et al., Treatment of children and young adults with early-stage non-Hodgkin's lymphoma, N Engl J Med, 337, pp. 1259-1266, (1997)

[19]

Reiter A., Schrappe M., Tiemann M., Et al., Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90, Blood, 94, pp. 3294-3306, (1999)

[20]

Patte C., Auperin A., Michon J., Et al., The Société Française d'Oncologie Pédiatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia, Blood, 97, pp. 3370-3379, (2001)

← 1 2 3 4 5 →